Omzar Iv (Esomeprazole)

Esomeprazole, the active ingredient in Omzar Iv, is a proton pump inhibitor presented as a strength/form for intravenous use. It reduces gastric acid secretion and is used to treat acid‑related disorders in adults. GNH USA supplies Omzar Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Omzar Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Omzar Iv is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑esophageal reflux disease (GERD): Improves healing of erosive esophagitis and relieves heartburn. - Peptic ulcer disease: Promotes ulcer healing and reduces recurrence. - Zollinger‑Ellison syndrome: Controls gastric acid hypersecretion associated with the syndrome.

Adverse reactions to esomeprazole may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Acute interstitial nephritis: kidney inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatotoxicity: elevated liver enzymes. - Anaphylaxis: life‑threatening allergic reaction.

When using Omzar Iv, several safety considerations should be observed: - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function. - Elderly patients: increased sensitivity to adverse effects. - Concomitant use with clopidogrel: may reduce antiplatelet effect. - Long‑term therapy: assess need periodically to avoid unnecessary exposure. - Store at below 25°C: keep in the original packaging, protect from moisture.

Esomeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activity. - Atazanavir: decreased absorption of the antiviral. - Dasatinib: lower plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR. - Phenytoin: reduced serum levels. - Ketoconazole: decreased absorption due to higher gastric pH.